We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Neuroinflammation
MedXY News
EnglishTag

Neuroinflammation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Metabolite-Mediated Neurocognitive Revival Following Liver Transplantation: Insights into Cortical Network Reactivation
GastroenterologyNeuroinflammationNeurocognitive Recovery

Metabolite-Mediated Neurocognitive Revival Following Liver Transplantation: Insights into Cortical Network Reactivation

By MedXY|Sep 3, 2026

Liver transplantation facilitates early neurocognitive recovery in end-stage liver disease patients by restoring cortical network activities, with S-methyl-5′-thioadenosine playing a pivotal neuroprotective role through modulating neu

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD
NeurologybiomarkersEBNA-1
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD

By MedXY|Mar 11, 2026

A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammat

Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression
Neurologybiomarkersmultiple sclerosis

Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression

By MedXY|Mar 10, 2026

**Refining Content Structure** I’m now deeply immersed in the content. I’ve drafted the introduction, designed to capture attention and set the scene. I am expanding on the key findings, including correlations, and the clinical

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS
Allergy & ImmunologyALSimmunotherapy

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS

By MedXY|Dec 31, 2025

A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad

NeurologyAzathioprineclinical trials

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

By MedXY|Dec 19, 2025

The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
Allergy & ImmunologyALSclinical trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY|Dec 6, 2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Allergy & ImmunologyAlzheimer's diseaselow-dose IL-2

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

By MedXY|Dec 6, 2025

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo

Anti-Inflammatory Diet and Alzheimer’s Disease Mortality: Insights from a National Cohort Study
Family Medicine & NutritionAlzheimer's diseaseAnti-inflammatory Diet

Anti-Inflammatory Diet and Alzheimer’s Disease Mortality: Insights from a National Cohort Study

By MedXY|Oct 6, 2025

Higher adherence to an anti-inflammatory diet is linked to lower all-cause mortality and a trend toward reduced Alzheimer’s disease mortality, particularly among men and non-Hispanic Whites, highlighting dietary modification as a pote

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities